Zentalis doses first patient in pivotal Phase 3 ASPENOVA trial for ovarian cancer drug

Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read

Key Changes

• high

  First patient dosed in Phase 3 ASPENOVA trial evaluating azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer, marking start of pivotal study designed to support full FDA approval.

  Item 7.01 verify on EDGAR →
• high

  Trial will enroll approximately 420 patients comparing azenosertib monotherapy against standard chemotherapy options (paclitaxel, pegylated liposomal doxorubicin, gemcitabine, or topotecan).

  Item 7.01 verify on EDGAR →
• high

  Trial design incorporates FDA feedback for accelerated approval pathway and requirements to convert to full approval, subject to data outcomes.

  Item 7.01 verify on EDGAR →